Initiator Pharma A/S (OM: INIT)
Health Care · Biotechnology · DK
Skr2.59
+4.86% today · -24.0% 1Y
Initiator Pharma A/S (OM: INIT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $18.72M and employs 1 people.
Over the last twelve months the share price has lost 24.0%, trading between 2.14 and 4.07.
Tweenvest scores Initiator Pharma A/S across four factors: quality 26/100. Its strongest factor is quality.
INIT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $18.72M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- 0.02
- 52-week high
- Skr4.07
- 52-week low
- Skr2.14
- Avg volume (3M)
- —
- Shares outstanding
- 68.45M
- Employees
- 1
- Next earnings
- —
About Initiator Pharma A/S
Initiator Pharma A/S is a clinical-stage life sciences firm dedicated to discovering therapeutic solutions for critical unmet medical needs affecting the central and peripheral nervous systems. Its development pipeline features several clinical-phase compounds: IP2018, a monoamine reuptake inhibitor aimed at psychogenic erectile dysfunction; IPED2015, designed to address organic erectile dysfunction; and IPTN2021, an orphan drug candidate for severe neuropathic pain. Additionally, the company holds early-stage assets, including IPNP2015 for chronic pain management and IPDP2015 for depression. Established in 2016, Initiator Pharma A/S maintains its headquarters in Copenhagen, Denmark.
- ISIN
- DK0060775872
- Founded
- 2016
- Listed since
- Mar 16, 2017
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.